埃索美拉唑与奥美拉唑治疗胃溃疡的疗效比较(1)
 |
| 第1页 |
参见附件(3065KB，3页)。
[摘要] 目的 探讨埃索美拉唑与奥美拉唑治疗胃溃疡的疗效比较。 方法 80例伴幽门螺杆菌(Hp)感染的胃溃疡患者随机分为两组各40例。治疗组前2周给予埃索美拉唑为主的Hp根除三联方案(埃索美拉唑20 mg，阿莫西林1.0 g，克拉霉素0.5 g，均1日2次)，2周后只用埃索美拉唑治疗6周；对照组前2周给予奥美拉唑为主的Hp根除三联方案(奥美拉唑20 mg，阿莫西林1.0 g，克拉霉素0.5 g，均1日2次)，2周后只用奥美拉唑治疗6周。评价和比较临床症状的缓解率、溃疡的愈合率、Hp的根除率、夜间酸突破发生率及用药后的不良反应。 结果 治疗后两组临床症状均有显著改善(P < 0. 05)，治疗组临床症状改善优于对照组(P < 0. 05)。溃疡愈合有效率、Hp根除率和夜间酸突破发生率治疗组均优于对照组(P < 0. 05)。 结论 埃索美拉唑治疗胃溃疡的疗效优于奥美拉唑,值得本地区临床推广。
[关键词] 埃索美拉唑；奥美拉唑；胃溃疡;幽门螺杆菌
[中图分类号] R573.1 [文献标识码] B [文章编号] 1673-9701(2012)03-0083-02
Efficacy comparison between esomeprazole and omeprazole in treating of gastric ulcer
HU Hui HU Haiyan
Department of Pharmacy, Hangzhou Frist People's Hospital in Zhejiang Province, Hangzhou 310006, China
[Abstract] Objective To investigate the effect of esomeprazole and omeprazole in the treatment of gastric ulcer. Methods Totally 80 patients with gastric ulcer and Hp infection were randomly divided into two groups with 40 cases in each. group A treated with esomeprazole-based triple therapy (esomeprazole 20 mg. bid and amoxicillin 1000mg. bid and clarithromycin 500 mg. bid) for two weeks ,then treated with esomeprazole for six weeks, group B treated with omeprazole-based triple therapy (omeprazole 20 mg. bid and amoxicillin 1000 mg. bid and clarithromycin 500 mg. bid) for two weeks,then treated with omeprazole for six weeks. After which clinical symptoms relief rate ,ulcer healing rate, eradication rate of Hp and nocturnal acid breakthough incidence as well as adverse effects of the medication were evaluated and compared. Results The clinical symptom had signally got better after the treatment (P < 0.05), and groupA was superior to group B (P <0.05), also with the ulcer healing rate, Hp eradication rate and nocturnal acid breakthough incidence (P < 0.05). Conclusion Esomeprazole is superior to omeprazole in the treatment of gastric ulcer and recommended to the local clinic.
[Key words] Esomeprazole;Omeprazole;Gastric ulcer;Hp
胃溃疡(GU)是临床常见和多发性疾病，具有发病率高、治疗周期长和复发率高等特点。现代社会生活节奏加快, 压力大, 生活不规律, 损伤因素多, 胃溃疡的发病率因此有所提高。基于“无酸无溃疡”和“无幽门螺杆菌无溃疡”的理论，质子泵抑制剂(PPI)就成为治疗胃溃疡的首选药。PPI 类药物的研究一直方兴未艾。2001年上市的埃索美拉唑因其独特的药代动力学特性而与以往的PPI明显不同[1] 。为了解埃索美拉唑治疗胃溃疡的疗效，本研究前瞻性收集胃溃疡患者，随机分组，对照观察埃索美拉唑与奥美拉唑在治疗胃溃疡后症状缓解、溃疡愈合及幽门螺杆菌(Hp)根除率方面的对比 ......
您现在查看是摘要介绍页，详见PDF附件(3065KB，3页)。